NCT00729742 2016-04-04Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)Merck Sharp & Dohme LLCPhase 1 Completed49 enrolled